Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gatralimab in Progressive Multiple Sclerosis
NCT02977533Phase 1Completed
- Sponsor
- Sanofi
- Start
- Dec 2016
- Primary completion
- May 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in multiple sclerosis (MS) comparing GZ402668 with Placebo (2 arms). Primary endpoint: Number of participants with treatment emergent adverse events at 4 weeks. Started Dec 2016; status: completed.
02
Drugs
gatralimab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02977533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02977533.